NewAmsterdam Pharma to Attend Investor Conferences
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is a leading biopharmaceutical firm committed to creating innovative oral medications designed to reduce low-density lipoprotein (LDL) cholesterol levels for individuals at risk of cardiovascular disease (CVD). The company is preparing for a series of upcoming investor conferences where its management will share the latest updates and future strategies.
Upcoming Conferences
Representatives from the company are set to participate in key industry events, providing a platform to engage directly with investors and share insights about their promising pipeline:
- Morgan Stanley 22nd Annual Global Healthcare Conference. This conference will be held in New York City. On September 5, company management will conduct one-on-one meetings, followed by a key presentation by Ian Somaiya, the Chief Financial Officer, on September 6 at 10:00 a.m. ET.
- Cantor Global Healthcare Conference. This event is scheduled for September 17, where Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya will participate in a fireside chat at 3:40 p.m. ET.
These conferences will offer valuable opportunities for investors to gain insights into NewAmsterdam's strategic direction, particularly as it seeks to address unmet medical needs within the CVD therapeutic area.
Webcasts Available
If you are unable to attend the conferences in person, live webcasts of the presentations will be available through the investor relations section of the NewAmsterdam Pharma website. Additionally, recordings of the events will be archived for later viewing, ensuring that all interested parties can stay informed about the discussions that occurred.
About NewAmsterdam Pharma
NewAmsterdam Pharma (Nasdaq: NAMS) is leading the way in developing therapies for metabolic diseases where current treatments fall short. The company's mission is to provide effective, safe, and well-tolerated medications aimed at lowering LDL cholesterol levels.
Currently, NewAmsterdam is conducting several phase 3 studies on obicetrapib, an oral, low-dose CETP inhibitor intended for daily use. This medication can serve as a complementary therapy alongside statins for patients who do not respond adequately to standard treatments.
Company Contact Information
For more information, you can contact Matthew Philippe at 1-917-882-7512 or via email at matthew.philippe@newamsterdampharma.com.
Contact for Media and Investor Relations
For media inquiries, please reach out to Bryan Blatstein at Spectrum Science. He is available at 1-917-714-2609 or via email at bblatstein@spectrumscience.com. For investor relations, contact Austin Murtagh at 1-212-698-8696 or austin.murtagh@precisionaq.com.
Frequently Asked Questions
What is NewAmsterdam Pharma known for?
NewAmsterdam Pharma specializes in developing oral, non-statin therapies aimed at reducing LDL cholesterol for patients at risk of cardiovascular disease.
What conferences will NewAmsterdam attend?
The company will be participating in the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference.
What is the significance of these conferences?
These conferences provide an opportunity for management to highlight their advancements and engage with investors regarding the company’s strategies and product pipeline.
How can I access the conference presentations?
Live webcasts of the presentations will be available on NewAmsterdam's investor relations website, with archived versions accessible later.
Who can I contact for more information about NewAmsterdam?
You can contact Matthew Philippe for inquiries or further details about the company's initiatives.
